Gynaecological Follow-up of a Subset of HPV-015 Study Subjects
Phase of Trial: Phase III
Latest Information Update: 01 Nov 2019
Price : $35 *
At a glance
- Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary)
- Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals
- 13 May 2019 This trial has been completed in UK as per European Clinical Trials Database.
- 25 Oct 2017 Status changed from recruiting to completed.
- 18 Jul 2016 Planned End Date changed from 1 Nov 2017 to 1 Jan 2018.